Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: STD Clear all
Completed Phase 3 Interventional

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

NCT00002166
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Durability of Adherence in Self-Management of HIV

NCT00991302
View directory record Official record
Conditions
HIV Infections
Interventions
CAP-IT
Behavioral
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions
Pioglitazone, Exercise Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
28 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 18, 2026, 5:36 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Face and Bones

NCT00001762
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing of a Navigation Intervention for Hepatitis C and HIV

NCT04499651
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Hepatitis C
Interventions
Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional

ART-CHESS: A Mobile Health Application to Support People Living With HIV and Addiction

NCT03873129
View directory record Official record
Conditions
HIV/AIDS, Substance Use Disorders
Interventions
mobile health app (mHealth)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

NCT00002003
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Mitoxantrone hydrochloride, Etoposide
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 5:36 AM EDT
Completed No phase listed Observational

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

NCT00312169
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Fresno, California • Los Angelos, California • Tarzana, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

NCT01093417
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Project SMART Automated Pillbox Study

NCT04418076
View directory record Official record
Conditions
HIV/AIDS, Cocaine Use
Interventions
Group A_No feedback, Group B_Automated feedback, Group C_Automated feedback + Clinician feedback, Group D_Automated feedback + Social Network feedback
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

NCT00002117
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Harbor City, California • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 4 Interventional Results available

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

NCT00239733
View directory record Official record
Conditions
Thrombocytopenia, Hepatitis C, HIV Infections
Interventions
Anti-D
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional

Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

NCT00002035
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
17
States / cities
Tucson, Arizona • New Haven, Connecticut • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 18, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

NCT00142740
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

The SOLVE-IT National Randomized Trial

NCT00653991
View directory record Official record
Conditions
HIV Infections
Interventions
SOLVE-IT
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 18, 2026, 5:36 AM EDT
Completed No phase listed Observational

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

NCT04065347
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication
Interventions
Digital Pill
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

TAKE Steps: Motivational Interviewing to Prevent STIs

NCT05215262
View directory record Official record
Conditions
Self Efficacy, HIV Prevention, STI Prevention
Interventions
Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 19 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

NCT00000795
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Peptide Immunogen, Multivalent
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 18, 2026, 5:36 AM EDT
Completed No phase listed Observational

A Study of Anal Cancer Development in HIV Infected People

NCT00107679
View directory record Official record
Conditions
HIV Infections, Anus Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 18, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527
View directory record Official record
Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 5:36 AM EDT